Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
University of Minnesota · University of North Carolina at Chapel Hill · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
220
total citations
- FWCI
- 42.80
- Percentile
- 100%
- References
- 45
Citations per year
Authors
108Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Randomized controlled trial
- Internal medicine
- Hydroxychloroquine
- Coronavirus disease 2019 (COVID-19)
- Pediatrics
- Alternative medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BABill and Melinda Gates FoundationAward: INV-017069
- ELEli Lilly and Company
- AAstraZeneca
- SSanofi
- ICIndiana Clinical and Translational Sciences Institute
- UOUniversity of MinnesotaAward: UL1TR002494
- MCMannKind Corporation
- LLeidos
- DDexcom
- FGFast Grants
- RCRainwater Charitable Foundation
- UGUnitedHealth Group
- MModerna
- NNNovo Nordisk
- NINational Institutes of HealthAwards: U54 CA210190, K23HL133604, R01LM012982, K23 DK124654-01-A1, OT2HL156812, UL1TR002489, R21LM012744, KL2TR002492, UM1TR004406, UL1TR002494, COVID-19, OT2HL161847, P01 CA254849
- NHNational Heart, Lung, and Blood InstituteAwards: UL1TR002494, OT2HL156812, OT2HL161847, T32HL129956
- NCNational Cancer InstituteAwards: CA210190, UL1TR002494, U54 CA210190, P01 CA254849
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAwards: DK124654, UL1TR002494
- NCNational Center for Advancing Translational SciencesAwards: UL1TR002494, UM1TR004406, KL2TR002492, UL1TR002489
- NINational Institute on Minority Health and Health Disparities